161 related articles for article (PubMed ID: 38526046)
21. In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae.
Tóth Z; Forgács L; Locke JB; Kardos G; Nagy F; Kovács R; Szekely A; Borman AM; Majoros L
J Antimicrob Chemother; 2019 Dec; 74(12):3505-3510. PubMed ID: 31539426
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.
Brzankalski GE; Najvar LK; Wiederhold NP; Bocanegra R; Fothergill AW; Rinaldi MG; Pattterson TF; Graybill JR
J Antimicrob Chemother; 2008 Nov; 62(5):1094-100. PubMed ID: 18658194
[TBL] [Abstract][Full Text] [Related]
23. Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481440
[TBL] [Abstract][Full Text] [Related]
24. Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014.
Liu WL; Lai CC; Li MC; Wu CJ; Ko WC; Hung YL; Tang HJ; Hsueh PR
J Microbiol Immunol Infect; 2019 Aug; 52(4):612-619. PubMed ID: 28886952
[TBL] [Abstract][Full Text] [Related]
25. Caspofungin-non-susceptible Candida isolates in cancer patients.
Kofteridis DP; Lewis RE; Kontoyiannis DP
J Antimicrob Chemother; 2010 Feb; 65(2):293-5. PubMed ID: 20016020
[TBL] [Abstract][Full Text] [Related]
26. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
27. In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms.
Ko KS; Lee JY; Song JH; Peck KR
J Korean Med Sci; 2010 Dec; 25(12):1722-6. PubMed ID: 21165285
[TBL] [Abstract][Full Text] [Related]
28. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.
Wang E; Farmakiotis D; Yang D; McCue DA; Kantarjian HM; Kontoyiannis DP; Mathisen MS
J Antimicrob Chemother; 2015 Aug; 70(8):2362-8. PubMed ID: 25855759
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections across urban Beijing, China.
Guo LN; Xiao M; Cao B; Qu F; Zhan YL; Hu YJ; Wang XR; Liang GW; Gu HT; Qi J; Yuan H; Min R; Wang FY; Liu LJ; Wang HB; Jiang W; Duan XG; Xu WJ; Yu YH; Su JR; Zhang JZ; Nong JQ; Liu SM; Li J; Liu JT; Yue ZG; Yang D; Guo J; Zhao R; Zhang YN; Yang XM; Liu XQ; Hsueh PR; Xu YC
Future Microbiol; 2017 Sep; 12():1075-1086. PubMed ID: 28836465
[TBL] [Abstract][Full Text] [Related]
30. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
Doğan Ö; Yeşilkaya A; Menekşe Ş; Güler Ö; Karakoç Ç; Çınar G; Kapmaz M; Aydın M; Keske Ş; Şahin S; Hacıseyitoğlu D; Yalçın D; Tekin S; Ataç N; Albayrak Ö; Aksu ED; Can F; Ergönül Ö
Int J Antimicrob Agents; 2020 Jul; 56(1):105992. PubMed ID: 32335275
[TBL] [Abstract][Full Text] [Related]
31. Invasive
Oliva A; De Rosa FG; Mikulska M; Pea F; Sanguinetti M; Tascini C; Venditti M
Expert Rev Anti Infect Ther; 2023; 21(9):957-975. PubMed ID: 37494128
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses.
Domingos EL; Vilhena RO; Santos JMMF; Fachi MM; Böger B; Adam LM; Tonin FS; Pontarolo R
Int J Antimicrob Agents; 2022 Aug; 60(2):106614. PubMed ID: 35691603
[TBL] [Abstract][Full Text] [Related]
33. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.
Wiederhold NP; Najvar LK; Bocanegra RA; Kirkpatrick WR; Patterson TF
Antimicrob Agents Chemother; 2011 Jul; 55(7):3254-60. PubMed ID: 21502632
[TBL] [Abstract][Full Text] [Related]
34. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.
Lortholary O; Desnos-Ollivier M; Sitbon K; Fontanet A; Bretagne S; Dromer F;
Antimicrob Agents Chemother; 2011 Feb; 55(2):532-8. PubMed ID: 21078946
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
36. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
Jarque I; Tormo M; Bello JL; Rovira M; Batlle M; Julià A; Tabares S; Rivas C; Fernández-Sevilla A; García-Boyero R; Debén G; González-Campos J; Capote FJ; Sanz MA;
Med Mycol; 2013 Feb; 51(2):150-4. PubMed ID: 22712457
[TBL] [Abstract][Full Text] [Related]
37. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA
Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
[TBL] [Abstract][Full Text] [Related]
38. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.
Desnos-Ollivier M; Bretagne S; Raoux D; Hoinard D; Dromer F; Dannaoui E;
Antimicrob Agents Chemother; 2008 Sep; 52(9):3092-8. PubMed ID: 18591282
[TBL] [Abstract][Full Text] [Related]
39. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.
Eschenauer GA; Nguyen MH; Shoham S; Vazquez JA; Morris AJ; Pasculle WA; Kubin CJ; Klinker KP; Carver PL; Hanson KE; Chen S; Lam SW; Potoski BA; Clarke LG; Shields RK; Clancy CJ
Antimicrob Agents Chemother; 2014; 58(4):1897-906. PubMed ID: 24395235
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.
Taj-Aldeen SJ; Kolecka A; Boesten R; Alolaqi A; Almaslamani M; Chandra P; Meis JF; Boekhout T
Infection; 2014 Apr; 42(2):393-404. PubMed ID: 24352810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
